Expensive CAR-T based immunotherapy will be reimbursed in Belgium

From June 1st, CAR-T based therapy to treat specific acute leukemia and B-cell lymphoma patients, will be reimbursed by the health insurance.

Minister Maggie De Block decides to pay for the treatment with CAR-T cells for these two groups :

• children and young adults with acute lymphatic leukemia in which other treatment fails.
• adults with an aggressive form of lymph node cancer (diffuse large B-cell lymphoma).

Het nieuwsblad (25 May) published an article (in Dutch) with explanation by CRIG group leader prof. Tessa Kerre.